It promised to be the best TPD meeting of the year with everyone from across the rapidly expanding array of TPD companies converging on Boston to share their latest data. Well, the Boston part didn’t materialise for obvious global reasons but it was still a great meeting with several hundred leading TPD scientists from around […]
This author has not written his bio yet.
But we are proud to say that ginealach contributed 55 entries already.
Entries by ginealach
Discovering new drugs is hard. It’s not rocket science – in fact, it’s much harder than rocket science! When new rockets are designed, they generally work successfully almost all of the time. However, with new drug discovery projects, they fail most of the time, in fact >95% of the time. There’s a wide variety of […]
Glasgow, Scotland, 21 May 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr Ian Churcher as Chief Scientific Officer (CSO). Amphista’s CEO Dr Nicola Thompson said, “I’m delighted to welcome Ian to the team. As an […]
La Biotech – View full story
Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based BioMotiv Glasgow, Scotland, 7 April 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins, […]